Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study

Assaf Arie Barg, Sarina Levy-Mendelovich, Einat Avishai, Rima Dardik, Mudi Misgav, Gili Kenet, Tami Livnat

Research output: Contribution to journalArticlepeer-review

Abstract

Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis.

Original languageEnglish
Article numbere27381
JournalPediatric Blood and Cancer
Volume65
Issue number12
DOIs
StatePublished - Dec 2018

Keywords

  • FEIBA
  • hemophilia B
  • inhibitor
  • rFVIIa
  • thrombin generation

Fingerprint

Dive into the research topics of 'Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study'. Together they form a unique fingerprint.

Cite this